Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR) announced that data from its Phase 1 clinical trial of CTI-1601 for treating Friedreich's ataxia will be presented at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, on May 26, 2022. The posters will cover the increase of tissue frataxin levels post-administration and the safety and pharmacokinetics of the therapy. This highlights Larimar's focus on developing treatments for complex rare diseases and advancing its clinical programs.

Positive

• Data from the Phase 1 clinical trial of CTI-1601 will be presented, indicating ongoing development.
• Focus on treating Friedreich's ataxia shows commitment to addressing complex rare diseases.

Negative

• None.

BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich's ataxia will be featured in two upcoming poster presentations at the 4^th Pan American Parkinson’s Disease and Movement Disorders Congress, which is taking place May 26 – 28, 2022 at the Hyatt Regency Miami in Miami, Florida.

Details on the poster presentations are shown below.

Title:	Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia
Abstract Number:	9
Poster Category:	Clinical Trials and Pharmacology
Presenting Author:	Russell G. Clayton, D.O., Principal, Aeremedea LLC
Presentation Date:	May 26, 2022
Presentation Time:	1:00 – 2:30 PM ET

Title:	Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Dose Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia
Abstract Number:	10
Poster Category:	Clinical Trials and Pharmacology
Presenting Author:	Russell G. Clayton, D.O., Principal, Aeremedea LLC
Presentation Date:	May 26, 2022
Presentation Time:	1:00 – 2:30 PM ET

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:	Company Contact:
Joyce Allaire	Michael Celano
LifeSci Advisors	Chief Financial Officer
jallaire@lifesciadvisors.com	mcelano@larimartx.com
(212) 915-2569	(484) 414-2715

FAQ

What is the significance of the upcoming presentations for Larimar Therapeutics (LRMR)?

The presentations will showcase data from the Phase 1 clinical trial of CTI-1601, indicating progress in its development for Friedreich's ataxia.

When are the poster presentations for Larimar Therapeutics scheduled?

The poster presentations are scheduled for May 26, 2022, during the Pan American Parkinson’s Disease and Movement Disorders Congress.

What will be discussed in Larimar Therapeutics' poster presentations at the congress?

The presentations will discuss the increase of tissue frataxin levels and the safety, tolerability, and pharmacokinetics of CTI-1601.

What is CTI-1601 being developed for by Larimar Therapeutics?

CTI-1601 is being developed as a treatment for Friedreich's ataxia.

Where and when is the Pan American Parkinson’s Disease and Movement Disorders Congress taking place?

The congress is taking place from May 26 to 28, 2022, at the Hyatt Regency Miami in Miami, Florida.